NICE has recommended a new first-line treatment for adults with advanced bladder cancer, marking a significant breakthrough for patients facing this devastating disease.

Millions of people are set to benefit from earlier access to newer type 2 diabetes treatments – the biggest shake-up in care for a decade – as part of NICE’s commitment to re-evaluate priority ...

Women, older people and Black people less likely to receive an SGLT-2 inhibitor prescription for type 2 diabetes ...

Seven other digital technologies - Beat Better, Datos Health, Get Ready, Luscii vitals, Pumping Marvellous Cardiac Rehab Platform, R Plus Health and Sword Move - require more research before they can ...

In final draft guidance published today we've confirmed that we’re unable to recommend cerliponase alfa (also called Brineura and made by BioMarin) for routine NHS use in treating neuronal ceroid ...

Evidence-based recommendations on osimertinib (Tagrisso) with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer in adults. Last ...

Evidence-based recommendations on osimertinib (Tagrisso) for adjuvant treatment of stage 1b to 3a non‑small‑cell lung cancer after complete tumour resection in adults. Last reviewed: 26 February 2025 ...

Early value assessment (EVA) guidance on artificial intelligence technologies to help detect fractures on X-rays in urgent care. Last reviewed: 14 January 2025 Next review: This guidance will be ...

Evidence-based recommendations on elranatamab (Elrexfio) for treating relapsed and refractory multiple myeloma after 3 or more treatments in adults. Last reviewed: 11 December 2024 Next review: More ...

Evidence-based recommendations on exagamglogene autotemcel (Casgevy) for transfusion-dependent beta-thalassaemia in people 12 years and over. Last reviewed: 11 September 2024 Next review: More ...

Evidence-based recommendations on pembrolizumab (Keytruda) with trastuzumab and chemotherapy for untreated locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal ...

NICE is unable to make a recommendation on trastuzumab deruxtecan (Enhertu) for treating HER2-mutated advanced non-small-cell lung cancer in adults after platinum-based chemotherapy. This is because ...